<DOC>
	<DOCNO>NCT01320111</DOCNO>
	<brief_summary>AIM OF STUDY Primary Efficacy Variable : The primary study objective proof efficacy , measure progression free survival ( PFS ) treatment metastatic locally inoperable recurrent breast cancer . Progression-free survival ( PFS ) define time randomisation disease progression death . Secondary Efficacy Variables : - Clinical benefit ( CR+PR+SD ) - ORR ( CR+PR ) - Time progression - Time next Treatment ( TTT ) - Overall survival - Safety profile</brief_summary>
	<brief_title>Breast Cancer Study : Paclitaxel Versus Paclitaxel Plus Sorafenib Second- Third-line Treatment</brief_title>
	<detailed_description>Today breast carcinoma lead cancer type second frequent cause cancer death adult woman . This tumor remain challenge modern oncology despite recent advance introduce new class chemotherapy like taxanes antibody HER-2/neu positive tumor . Recently show combination conventional chemotherapy monoclonal antibody VEGF increase response progression free survival combination antiangiogenic therapy . It suppose effect might result prolonged survival . Sorafenib , new develop oral inhibitor tyrosine kinases responsible signal transduction bind VEGF receptor RAS-Raf-MEK-ERK pathway seem efficient treatment broad range tumor . The multi-kinase inhibitor Sorafenib target Raf/MEK/ERK pathway level Raf kinase receptor tyrosine kinases VEGFR-2 PDGFR-β , thereby affect , tumour vasculature . Preclinical study well phase I trials show anti-tumour activity patient metastatic breast cancer treat single-agent sorafenib . This multicentre , phase II , open-label , randomise study design ass potential prolongation progression free survival patient metastatic breast cancer combination standard chemotherapy paclitaxel compare paclitaxel monotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Histologically cytologically confirm adenocarcinoma breast 2 . HER2/neu negative ( primary tumour site HER2/neu negative ICH/FISH test ) 3 . Second till thirdline chemotherapy 4 . Female , age ≥ 18 year . 5 . ECOG Performance Status 0 1 ( KarnofskyIndex ≥ 70 % ) 6 . Life expectancy least 12 week . 7 . Subjects least one unidimensional ( RECIST 1.1 ) measurable lesion . Lesions must measure Xray ( pulmonary lesion ) CTscan MRI ( Patients measurable bone lesion also include , long meet criterion RECIST 1.1. ; mean , lytic bone lesion mixed lyticblastic bone lesion identifiable soft tissue component . ) 8 . No prior therapy locally recurrent metastatic disease TKI 's ( RAS/Raf , MEK , AKT ) , mTOR inhibitor angiogenesis inhibitor ( VEGV/VEGFR , PDGF/PDGFR ) bevacizumab allow . 9 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin ≥ 9.0 g/dl Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 Platelet count ≥ 100,000/μl Total bilirubin ≤ 1.5 x upper limit normal ALT AST ≤ 2.5 x upper limit normal ( &lt; 5 x upper limit normal patient liver involvement cancer ) Alkaline phosphatase ≤ 4 x upper limit normal PTINR PTT ≤ 1.5 x upper limit normal [ Patients therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist . ] Serum creatinine ≤ 1.5 x upper limit normal . 10 . Signed date informed consent start specific protocol procedure . 1 . History cardiac disease : congestive heart failure &gt; NYHA class 2 ; active CAD ( MI 6 month prior study entry allow ) ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension . 2 . Known history HIV infection chronic hepatitis B C 3 . Active clinically serious infection ( &gt; grade 2 NCICTC version 4.02 ) 4 . Prior clinical radiological evidence CNS metastases include previously treat , resect , asymptomatic brain lesion leptomeningeal involvement contrast enhance head CT scan MRI 5 . Patients seizure disorder require medication ( steroids antiepileptic ) 6 . History organ allograft 7 . Patients evidence history bleed diathesis 8 . Patients undergoing renal dialysis 9 . Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumour [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry . 10 . Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Women enrol trial must use adequate barrier birth control measure course trial . 11 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result 12 . Any condition unstable could jeopardise safety patient compliance study 13 . Patients unable swallow oral medication . 14 . Patients intolerance Paclitaxel . Excluded therapy medication , previous concomitant : 1 . Anticancer chemotherapy , hormonotherapy immunotherapy study within 3 week study entry . 2 . Radiotherapy within 3 week start study drug , palliative radiotherapy allow . 3 . Major surgery within 4 week start study 4 . Autologous bone marrow transplant stem cell rescue within 4 month study entry 5 . Use biologic response modifier , GCSF , within 3 week study entry . [ GCSF hematopoietic growth factor may use management acute toxicity febrile neutropenia clinically indicate discretion investigator ; however may substitute require dose reduction . ] [ Patients take chronic erythropoietin permit provide dose adjustment undertaken within 2 month prior study study ] 6 . Investigational drug therapy outside trial within 4 week study entry 7 . Previous treatment paclitaxel within 1.line 2.line palliative therapy ( Paclitaxel within ( neo ) adjuvant therapy allow )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>progression free survival</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>sorafenib</keyword>
	<keyword>metastatic breast cancer</keyword>
</DOC>